Pierre Fabre Medicament

R.p.scherer Technologies, Inc.

Joël Bougaret

Jean-Louis Avan

Elie Leverd

Roland Segonds

Michel Sournac

Marie-Dominique Ibarra

Marie-Madeleine Bohn

Norbert Heintz

Bruno Paillard

Isabel Ribeiro Dos Santos

Laurent Liorzou

Stable pharmaceutical composition consisting of a hydrosoluble vinflunine salt and at least one diluent and one lubricant, said composition being in the form of a solid intended for oral administration. The hydrosoluble vinflunine salt is preferably Vinflunine ditartrate. The pharmaceutical composition is advantageously in the form of a capsule or tablet. The invention also concerns a method of treating cancer pathology comprising the oral administration of the pharmaceutical composition of the invention.

Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt

This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30 000.

Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it

A pharmaceutical composition comprising idazoxan or derivatives and their therapeutically acceptable salts, racemates, optically active isomers and polymorphs.

Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof

This invention relates to pharmaceutical compositions consisting of a semisynthetic derivative of vinca alkaloid, stable at room temperature, in which said derivative is present in the form of a freeze dried product obtained in the presence of at least one carbohydrate.

Freeze-dried injectable pharmaceutical combination of semisynthetic vinca alkaloids and carbohydrate stable at room temperature

Pharmaceutical composition comprising 5 to 20% of an idazoxan salt or of idazoxan hydrate, 10 to 40% of microcrystalline cellulose, 1 to 5% of lubricant, 0.1 to 0.5% of colloidal silica and from 29.5% to 84.8% of lactose, with respect to the total mass.

The invention described herein relates to a pharmaceutical composition containing vinorelbine as an active ingredient which is suitable for encapsulation in soft capsules. The liquid oral pharmaceutical composition suitable for a liquid fill composition for a soft capsule dosage form comprises: vinorelbine or a pharmaceutically acceptable salt thereof; ethanol; water; glycerol; and polyethylene glycol. In a preferred embodiment, the tartrate salt form of vinorelbine is used in the composition. The invention also provides for a method of treating cancer comprising orally administering, to a patient in need of treatment thereof, a soft capsule comprising the pharmaceutical composition of the invention.

Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment

Pharmaceutical composition based on a polymorphic form I of idazoxan

The invention relates to a self-adhesive transdermal device for the administration of testosterone and/or at least one of the derivatives thereof, comprising successively at least one support layer, a self-adhesive matrix layer and a detachable protective layer, whereby the matrix layer comprises at least one self-adhesive polymer, at least one formulating adjuvant for the matrix layer, at least one solvent chosen from the group made up of solvents of testosterone or the derivatives thereof and testosterone and/or at least one of the derivatives thereof in an oversaturated solution. The device has excellent testosterone permeation qualities and excellent cutaneous tolerance and adhesion qualities. The invention also relates to a method for the production of said device and the use thereof for a medicament, i.e. within the framework of a testosterone replacement therapy.

Transdermal device for administering testosterone or one of the derivatives thereof

The present invention relates to a sustained-release tablet, characterized in that it comprises as active principle isosorbide 5-mononitrate (5-ISMN) in the form of a powder having a particle size of 80 .mu.m to 500 .mu.m, in homogeneous dispersion in a hydrophilic matrix based on at least one swelling component and at least one diluent component.

Sustained-release tablet based on isosorbide 5-mononitrate and process

The present invention relates to tablets of the type which contain a homogeneous dispersion of an active principle based on salbutamol or on one of its derivatives in a hydrophilic matrix, ensuring:

Growing community of inventors

Francarville, France

Joël Bougaret